


Jubilant Biosys strengthens footprint in Europe for Biologics and Antibody Drug Conjugate services

13 February 2025 | News

Brings together a complementary innovator customer base



Jubilant Biosys Innovative Research Services Pte Limited, Singapore (JBIRSPL), a subsidiary of Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited, has executed the transaction definitive agreements with Pierre Fabre (PF) SA, and its affiliate entities, for JBIRSPL to acquire 80% equity capital in JASMIN (new company incorporated by PF in France, as a Société par Actions Simplifiée (SAS)), with remaining 20% retained by PF.

At closing of the transaction, JASMIN shall acquire Pierre Fabre's R&D Centre (including R&D Site and R&D activities) at Saint-Julien-en-Genevois, France, and JBIRSPL would also execute a Shareholders' Agreement and other transition agreements with PF.

This strategic agreement will enable Jubilant Biosys Limited to expand its footprint in Europe in areas like Biologics (mAbs) and Antibody Drug Conjugate (ADC), in addition to its existing services including integrated drug discovery services from India.

This serves as an opportunity to significantly expand the company's customer connections with large pharmaceutical companies due to proximity to EU/US markets, which have a preference for local contract research organisation (CRO) interactions. The collaboration will help create significant cross-selling potential to customer bases across small-to-mid

biotech and large innovator pharma.

Giuliano Perfetti, CEO & Managing Director, Jubilant Biosys said, "Our R&D site in Saint-Julien-en-Genevois will serve as a Center of Excellence for biologics and ADCs, located at the heart of Europe. This expansion strengthens our presence and fosters collaboration with both biotech and large pharma companies in Europe and the USA. By combining the scientific expertise in biologics and ADCs at Saint-Julien-en-Genevois with the capabilities of 1,200 scientists in India we establish a comprehensive service offering for accelerated delivery of early chemistry, discovery biology, DMPK, integrated drug discovery and CDMO for intermediates and APIs. With this strategic move, Jubilant Biosys Limited advances its "CRDMO Partner in Science" strategy and reinforces its commitment to delivering innovative solutions to global pharmaceutical customers."